Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma

Published:2016-10-24 Issue:12 Volume:5 Page:3464-3474
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Pericay Carles¹,Rivera Fernando²,Gomez-Martin Carlos³,Nuñez Inmaculada⁴,Cassinello Alejo⁴,Imedio Esteban Rodrigo⁴

Affiliation:

1. Department of Oncology; Sabadell University Hospital; Parc Tauli Sabadell Spain

2. Department of Medical Oncology; Hospital Universitario Santander; Santander Spain

3. Gastrointestinal Cancer and Early Clinical and Translational Research Units; 12 de Octubre University Hospital; Madrid Spain

4. Eli Lilly and Company; Alcobendas Madrid Spain

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.941/fullpdf

Reference56 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012;Ferlay;Eur. J. Cancer,2013

3. From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer;Murphy;Gastroenterol. Res. Pract. [online].,2015

4. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease;Buas;Semin Radiat. Oncol.,2013

5. Management of gastric cancer;Ku;Curr. Opin. Gastroenterol.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy;Frontiers in Oncology;2023-01-04

2. Is ramucirumab still the only second-line treatment in metastatic gastric cancer?;Pharmacogenomics;2020-11

3. Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases;SAGE Open Medical Case Reports;2020-01

4. Different administration methods of endostar combined with second-line chemotherapy in advanced malignancies;Indian Journal of Cancer;2020

5. Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro;Cirugía Española;2019-10